Anthony T Newall

List of Publications by Year
in descending order

88 papers	4,845 citations	172207 29 h-index	102304 66 g-index
89 all docs	89 docs citations	89 times ranked	8120 citing authors

#	Article	IF	Citations
1	Effectiveness of 7-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Medically At-Risk Children in Australia: A Record Linkage Study. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 391-399.	0.6	2
2	Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009â€“2017. Influenza and Other Respiratory Viruses, 2022, 16, 1082-1090.	1.5	3
3	Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine, 2021, 39, 512-520.	1.7	63
4	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	1.2	5
5	Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage. Vaccine, 2021, 39, 1727-1735.	1.7	6
6	Rotavirus Vaccination Likely to Be Cost Saving to Society in the United States. Clinical Infectious Diseases, 2021, 73, 1424-1430.	2.9	4
7	Estimating pertussis incidence in general practice using a large Australian primary care database. Vaccine, 2021, 39, 4153-4159.	1.7	1
8	Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017. Vaccine, 2021, 39, 7578-7583.	1.7	2
9	How can early stage economic evaluation help guide research for future vaccines?. Vaccine, 2021, 40, 175-175.	1.7	2
10	Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study. Clinical Infectious Diseases, 2020, 71, 340-350.	2.9	9
11	Financial cost analysis of a strategy to improve the quality of administrative vaccination data in Uganda. Vaccine, 2020, 38, 1105-1113.	1.7	3
12	Delay-adjusted age- and sex-specific case fatality rates for COVID-19 in South Korea: Evolution in the estimated risk of mortality throughout the epidemic. International Journal of Infectious Diseases, 2020, 101, 306-311.	1.5	12
13	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2020, 23, e25494.	1.2	5
14	High healthcare resource utilisation due to pertussis in Australian adults aged 65Âyears and over. Vaccine, 2020, 38, 3553-3559.	1.7	5
15	Rapid mapping of the spatial and temporal intensity of influenza. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1307-1312.	1.3	1
16	Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine, 2019, 37, 7534.	1.7	0
17	Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. Vaccine, 2019, 37, A132-A139.	1.7	43
18	Rationale and opportunities in estimating the economic burden of seasonal influenza across countries using a standardized <scp>WHO</scp> tool and manual. Influenza and Other Respiratory Viruses, 2018, 12, 13-21.	1.5	15

#	Article	IF	Citations
19	The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia. Vaccine, 2018, 36, 1265-1271.	1.7	10
20	Influenzaâ€associated mortality in South Africa, 2009â€2013: The importance of choices related to influenza infection proxies. Influenza and Other Respiratory Viruses, 2018, 12, 54-64.	1.5	6
21	Use of the letter-based grading information disclosure system and its influence on dining establishment choice in Singapore: A cross-sectional study. Food Control, 2018, 90, 105-112.	2.8	11
22	Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. Vaccine, 2018, 36, 3199-3207.	1.7	118
23	Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine, 2018, 36, 2057-2060.	1.7	4
24	WHO guide on the economic evaluation of influenza vaccination. Influenza and Other Respiratory Viruses, 2018, 12, 211-219.	1.5	25
25	Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet, The, 2018, 391, 1285-1300.	6.3	1,870
26	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine, 2018, 36, 6307-6313.	1.7	14
27	Economic burden of seasonal influenza in the United States. Vaccine, 2018, 36, 3960-3966.	1.7	309
28	Climate variability and salmonellosis in Singapore â€“ A time series analysis. Science of the Total Environment, 2018, 639, 1261-1267.	3.9	25
29	Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States. Vaccine, 2018, 36, 5910-5915.	1.7	22
30	Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program. Vaccine, 2018, 36, 4157-4160.	1.7	3
31	Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine, 2017, 35, 345-352.	1.7	23
32	Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine, 2017, 35, 4307-4314.	1.7	12
33	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health, The, 2017, 2, e367-e374.	4.7	72
34	Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China from respiratory infections. BMC Infectious Diseases, 2017, 17, 464.	1.3	29
35	Knowledge, attitudes and practices of Australian medical students towards influenza vaccination. Vaccine, 2016, 34, 6193-6199.	1.7	32
36	Assessing the impact of vaccination programmes on burden of disease: Underlying complexities and statistical methods. Vaccine, 2016, 34, 3022-3029.	1.7	2

#	Article	IF	Citations
37	Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. Pharmacoeconomics, 2016, 34, 723-731.	1.7	9
38	Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine, 2016, 34, 5442-5448.	1.7	63
39	Using Economic Evidence to Set Healthcare Priorities in Lowâ€Income and Lowerâ€Middleâ€Income Countries: A Systematic Review of Methodological Frameworks. Health Economics (United Kingdom), 2016, 25, 140-161.	0.8	59
40	What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?. Human Vaccines and Immunotherapeutics, 2016, 12, 2666-2669.	1.4	4
41	Comparison of influenza vaccination coverage between immigrant and Australian-born adults. Vaccine, 2016, 34, 6388-6395.	1.7	20
42	Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. Vaccine, 2016, 34, 320-327.	1.7	15
43	Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults. PLoS ONE, 2016, 11, e0160446.	1.1	3
44	Risk factors for herpes zoster in a large cohort of unvaccinated older adults: a prospective cohort study. Epidemiology and Infection, 2015, 143, 2871-2881.	1.0	33
45	Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested caseâ€“control study. Vaccine, 2015, 33, 5647-5653.	1.7	15
46	Review of economic evaluations of mask and respirator use for protection against respiratory infection transmission. BMC Infectious Diseases, 2015, 15, 413.	1.3	15
47	Risk factors and burden of acute Q fever in older adults in New South Wales: a prospective cohort study. Medical Journal of Australia, 2015, 203, 438-438.	0.8	13
48	A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Human Vaccines and Immunotherapeutics, 2015, 11, 818-825.	1.4	32
49	Control of varicella in the post-vaccination era in Australia: a model-based assessment of catch-up and infant vaccination strategies for the future. Epidemiology and Infection, 2015, 143, 1467-1476.	1.0	7
50	Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice. Pharmacoeconomics, 2015, 33, 1255-1268.	1.7	56
51	Acute myocardial infarction and influenza: a meta-analysis of caseâ€“control studies. Heart, 2015, 101, 1738-1747.	1.2	239
52	Factors associated with influenza vaccination in middle and older aged Australian adults according to eligibility for the national vaccination program. Vaccine, 2015, 33, 3299-3305.	1.7	33
53	Medicare Benefits Schedule data to monitor influenza immunisation in Australian adults. Public Health Research and Practice, 2015, 25, e2541543.	0.7	4
54	Inaccurate Ascertainment of Morbidity and Mortality due to Influenza in Administrative Databases: A Population-Based Record Linkage Study. PLoS ONE, 2014, 9, e98446.	1.1	25

#	Article	IF	Citations
55	Authorsâ€™ Reply to Gandjour: â€œAre Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccinesâ€• Pharmacoeconomics, 2014, 32, 1247-1247.	1.7	0
56	Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 425-435.	0.7	14
57	The cost-effectiveness of influenza vaccination in elderly Australians: An exploratory analysis of the vaccine efficacy required. Vaccine, 2014, 32, 1323-1325.	1.7	19
58	Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine, 2014, 32, 759-765.	1.7	16
59	Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines. Pharmacoeconomics, 2014, 32, 525-531.	1.7	88
60	Understanding the Cost-Effectiveness of Influenza Vaccination in Children: Methodological Choices and Seasonal Variability. Pharmacoeconomics, 2013, 31, 693-702.	1.7	19
61	Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 12-28.	0.7	27
62	Evidence for the aetiology of human papillomavirus in oesophageal squamous cell carcinoma in the Chinese population: a meta-analysis. BMJ Open, 2013, 3, e003604.	0.8	12
63	A Randomized Clinical Trial of Three Options for N95 Respirators and Medical Masks in Health Workers. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 960-966.	2.5	153
64	Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Human Vaccines and Immunotherapeutics, 2013, 9, 834-840.	1.4	35
65	Mortality Attributable to Seasonal and Pandemic Influenza, Australia, 2003 to 2009, Using a Novel Time Series Smoothing Approach. PLoS ONE, 2013, 8, e64734.	1.1	45
66	The Aetiological Role of Human Papillomavirus in Oesophageal Squamous Cell Carcinoma: A Meta-Analysis. PLoS ONE, 2013, 8, e69238.	1.1	67
67	Contact Tracing of Tuberculosis: A Systematic Review of Transmission Modelling Studies. PLoS ONE, 2013, 8, e72470.	1.1	33
68	Changes in seroprevalence to hepatitis A in Victoria, Australia: A comparison of three time points. Vaccine, 2012, 30, 6020-6026.	1.7	18
69	The cost and disease burden of pneumonia in general practice in Australia. Vaccine, 2012, 30, 830-831.	1.7	13
70	Under-explored assumptions in influenza vaccination models: Implications for the universal vaccination of children. Vaccine, 2012, 30, 5776-5781.	1.7	6
71	Which providers can bridge the health literacy gap in lifestyle risk factor modification education: a systematic review and narrative synthesis. BMC Family Practice, 2012, 13, 44.	2.9	57
72	A systematic review of interventions in primary care to improve health literacy for chronic disease behavioral risk factors. BMC Family Practice, 2012, 13, 49.	2.9	193

#	Article	IF	Citations
73	Economic Evaluations of Childhood Influenza Vaccination. Pharmacoeconomics, 2012, 30, 647-660.	1.7	20
74	The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine, 2011, 29, 8077-8085.	1.7	30
75	Uncertainty and variability in influenza costâ€effectiveness models. Australian and New Zealand Journal of Public Health, 2011, 35, 576-577.	0.8	0
76	Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiology and Infection, 2010, 138, 836-842.	1.0	35
77	Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1. Emerging Infectious Diseases, 2010, 16, 224-230.	2.0	27
78	Cost Effectiveness of Influenza Vaccination in Older Adults. Pharmacoeconomics, 2009, 27, 439-450.	1.7	26
79	The burden of rotavirus gastroenteritis in children presenting to a paediatric hospital. Epidemiology and Infection, 2009, 137, 943-949.	1.0	3
80	The cost-effectiveness of a universal influenza vaccination program for adults aged 50â€“64 years in Australia. Vaccine, 2008, 26, 2142-2153.	1.7	28
81	Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine, 2008, 26, 2135-2141.	1.7	67
82	Influenza-related disease: The cost to the Australian healthcare system. Vaccine, 2008, 26, 6818-6823.	1.7	60
83	Mortality benefits of influenza vaccination in elderly people. Lancet Infectious Diseases, The, 2008, 8, 462-463.	4.6	14
84	Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia. Clinical Infectious Diseases, 2008, 46, 1647-1655.	2.9	79
85	The cost-effectiveness of rotavirus vaccination in Australia. Vaccine, 2007, 25, 8851-8860.	1.7	61
86	Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases, The, 2007, 7, 289-296.	4.6	118
87	Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Communicable Diseases Intelligence Quarterly Report, 2007, 31 Suppl, S1-152.	0.6	13
88	Burden of severe rotavirus disease in Australia. Journal of Paediatrics and Child Health, 2006, 42, 521-527.	0.4	31